AIM ImmunoTech

AIM ImmunoTech Goodwill/Assets

Goodwill to Total Assets Ratio of AIM ImmunoTech (AIM) as of Oct 20, 2026.

Goodwill/Assets

0.00

Last updated:

Goodwill to Total Assets Ratio of AIM ImmunoTech is 2025 0.00 . Goodwill to Total Assets Ratio of AIM ImmunoTech was 2024 0.00 . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

AIM ImmunoTech Stock analysis

What does AIM ImmunoTech do? AIM ImmunoTech Inc is a biotechnology company based in Ocala, Florida, operating within the health care sector. The company focuses on the clinical development of drug therapies utilizing natural immune system enhancing technologies for treating viral and immune-based disorders. It employs 31 full-time staff members. AIM ImmunoTech's primary products include Alferon N Injection, approved for intralesional treatment of refractory or recurring external genital warts in patients over 18, and Ampligen, which is under clinical development for Chronic Fatigue Syndrome (CFS). The company also develops Alferon LDO, a low-dose oral liquid formulation of natural alpha interferon. AIM ImmunoTech went public on July 12, 1996, with its ticker symbol AIM and ISIN US00901B3033. Its website is hemispherx.net. The company's operations are centered around research and development activities related to Ampligen and other drugs in development, alongside sales and marketing of Alferon. The firm's activities are primarily directed toward addressing chronic viral and immune-related conditions through innovative therapeutic approaches. AIM ImmunoTech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AIM ImmunoTech stock

On Eulerpool you can find the complete historical development of Goodwill to Total Assets Ratio AIM ImmunoTech since 2006 – with annual values, charts, and detailed analysis.

The Goodwill/Assets ratio shows what percentage of total assets consists of acquisition goodwill. High ratios may indicate impairment risk.

Goodwill to Total Assets Ratio's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Goodwill to Total Assets Ratio's AIM ImmunoTech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — AIM ImmunoTech

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — AIM ImmunoTech